默沙东Merck & Co. Inc.（MRK）2025年第四季度及全年销售额及业绩报告「NYSE」（英文版）（34页）.pdf

1、Fourth-Quarter 2025 Sales and EarningsMerck&Co.,Inc.,Rahway,N.J.,USAFebruary 3,2026Agenda2Strategy and Business UpdateStrategy and Business UpdateRobert M.DavisChairman and Chief Executive OfficerAgendaFinancial Results and OutlookFinancial Results and OutlookCaroline LitchfieldExecutive Vice Presid

2、ent and Chief Financial OfficerResearch UpdateResearch UpdateDr.Dean Y.LiExecutive Vice President and President,Research LaboratoriesQuestion&Answer SessionQuestion&Answer SessionForward-looking statement of Merck&Co.,Inc.,Rahway,N.J.,USA3This presentation of Merck&Co.,Inc.,Rahway,N.J.,USA(the“compa

3、ny”)includes“forward-looking statements”within the meaning of the safe harbor provisions of the U.S.Private Securities Litigation Reform Act of 1995.These statements are based upon the current beliefs and expectations of the companys management and are subject to significant risks and uncertainties.

4、There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful.If underlying assumptions prove inaccurate or risks or uncertainties materialize,actual results may differ material

5、ly from those set forth in the forward-looking statements.Risks and uncertainties include but are not limited to,general industry conditions and competition;general economic factors,including interest rate and currency exchange rate fluctuations;the impact of pharmaceutical industry regulation and h

6、ealth care legislation in the United States and internationally;global trends toward health care cost containment;technological advances,new products and patents attained by competitors;challenges inherent in new product development,including obtaining regulatory approval;the companys ability to acc